CD123 binding agents and uses thereof

US9850310B2 · kind B2 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Francois Gaudet · Princeton, US
• Jennifer F. Nemeth · Fort Washington, US
• Ricardo Attar · Lawrenceville, US
• Benjamin Harman · Spring House, US
• Yingzhe Li · Dresher, US
• Jinquan Luo · Malvern, US
• Ronan McDaid · Eagleville, US
• Steven Pomerantz · Spring House, US
• Susan Tam · Boothwyn, US
• Alexey Teplyakov · Spring House, US
• John Wheeler · Spring House, US
• Sheng-Jiun Wu · Broomall, US

Key dates

• Filing date: Sep 3, 2015
• Grant date: Dec 26, 2017
• Expiry date: Sep 3, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/94
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided herein are antibodies that immunospecifically bind to CD123. Also described are related polynucleotides capable of encoding the provided CD123-specific antibodies or antigen-binding fragments, cells expressing the provided antibodies or antigen-binding fragments, as well as associated vectors and detectably labeled antibodies or antigen-binding fragments. In addition, methods of using the provided antibodies are described. For example, the provided antibodies may be used to diagnose, treat, or monitor CD123-expressing cancer progression, regression, or stability; to determine whether or not a patient should be treated for cancer; or to determine whether or not a subject is afflicted with CD123-expressing cancer and thus may be amenable to treatment with a CD123-specific anti-cancer therapeutic, such as the multispecific antibodies against CD123 and CD3 described herein.